Results 41 to 50 of about 8,272 (178)

Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis

Biochemistry and Biophysics Reports, 2023
Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition.
Daria V. Sizova, Steve Raiker, Deaneira Lakheram, Vishwanatha Rao, Andrew Proffitt, Yazen Jmeian, Walter Voegtli, Melissa Batonick   +7 more
doaj   +1 more source

A prospective study of nutritional status in immunoglobulin light chain amyloidosis

Haematologica, 2013
Weight loss is common in systemic immunoglobulin light chain amyloidosis but there are limited data on the impact of nutritional status on outcome.
Prayman T. Sattianayagam, Thirusha Lane, Zoe Fox, Aviva Petrie, Simon D.J. Gibbs, Jennifer H. Pinney, Signe S. Risom, Dorota M. Rowczenio, Ashutosh D. Wechalekar, Helen J. Lachmann, Janet A. Gilbertson, Philip N. Hawkins, Julian D. Gillmore   +12 more
doaj   +1 more source

Chronic myopathy due to immunoglobulin light chain amyloidosis [PDF]

Molecular Genetics and Metabolism, 2013
Amyloid myopathy associated with a plasma cell dyscrasia is a rare cause of muscle hypertrophy. It can be a challenging diagnosis, since pathological findings are often elusive. In addition, the mechanism by which immunoglobulin light-chain deposition stimulates muscle overgrowth remains poorly understood. We present a 53-year old female with a 10-year
Manoli, Irini, Kwan, Justin Y, Wang, Qian, Rushing, Elisabeth J, Tsokos, Maria, Arai, Andrew E, Burch, Warner M, Dispenzieri, Angela, McPherron, Alexandra C, Gahl, William A   +9 more
openaire   +4 more sources

A stepwise data interpretation process for renal amyloidosis typing by LMD-MS

BMC Nephrology, 2022
Backgrounds Systemic amyloidosis is classified according to the deposited amyloid fibril protein (AFP), which determines its best therapeutic scheme. The most common type of AFP found are immunoglobulin light chains.
Ming Ke, Xin Li, Lin Wang, Shuling Yue, Beibei Zhao   +4 more
doaj   +1 more source

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis [PDF]

Blood, 2012
Abstract Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma.
Angela, Dispenzieri, Francis, Buadi, Kristina, Laumann, Betsy, LaPlant, Suzanne R, Hayman, Shaji K, Kumar, David, Dingli, Steven R, Zeldenrust, Joseph R, Mikhael, Robert, Hall, S Vincent, Rajkumar, Craig, Reeder, Rafael, Fonseca, P Lief, Bergsagel, A Keith, Stewart, Vivek, Roy, Thomas E, Witzig, John A, Lust, Stephen J, Russell, Morie A, Gertz, Martha Q, Lacy   +20 more
openaire   +2 more sources

Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment [PDF]

Türk Patoloji Dergisi
Cardiac amyloidosis is a type of amyloidosis that deserves special attention as organ involvement significantly worsens the prognosis. Cardiac amyloidosis can be grouped under three main headings: immunoglobulin light chain (AL) amyloidosis that is ...
Asuman ARGON, Deniz NART, Funda YILMAZ BARBET   +2 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Light-chain amyloidosis with dysphagia as the main symptom: a case report

Journal of Medical Case Reports
Background Immunoglobulin light-chain amyloidosis is a relatively rare condition with a worldwide incidence of 5.1–12.8 cases per million person-years (Baker, 2022).
Maomao Ai, Tao Lin, Ruoyu Guo, Haiyao Zheng, Haiyan Deng, Feng Yu   +5 more
doaj   +1 more source

Cutaneous light chain amyloidosis with multiple myeloma: A concise review

Hematology/Oncology and Stem Cell Therapy, 2019
Objective/Background: Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well defined.
Mirela Andrei, Jen Chin Wang
doaj   +1 more source

Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney [PDF]

Blood, 2008
Abstract Introduction: The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy have not been well described in this patient group Patients: 145 patients with AL who participated
Morie A, Gertz, Nelson, Leung, Martha Q, Lacy, Angela, Dispenzieri, Steven R, Zeldenrust, Suzanne R, Hayman, Francis K, Buadi, David, Dingli, Philip R, Greipp, Shaji K, Kumar, John A, Lust, S Vincent, Rajkumar, Stephen J, Russell, Thomas E, Witzig   +13 more
openaire   +2 more sources